The Human Brainome: Changes in Expression of VGF, SPECC1L, HLA-DRA and RANBP3L Act with APOE E4 to Alter Risk for Late Onset Alzheimer's Disease

Overview

Journal Res Sq

Date 2024 Jan 3

PMID 38168398

Authors

Sergio Branciamore

Grigoriy Gogoshin

Andrei S Rodin

Amanda J Myers

Affiliations

Soon will be listed here.

Abstract

While there are currently over 40 replicated genes with mapped risk alleles for Late Onset Alzheimer's disease (LOAD), the E locus E4 haplotype is still the biggest driver of risk, with odds ratios for neuropathologically confirmed E44 carriers exceeding 30 (95% confidence interval 16.59-58.75). We sought to address whether the E4 haplotype modifies expression globally through networks of expression to increase LOAD risk. We have used the Human Brainome data to build expression networks comparing E4 carriers to non-carriers using scalable mixed-datatypes Bayesian network (BN) modeling. We have found that had the greatest explanatory weight. High expression of is a protective signal, even on the background of E4 alleles. LOAD risk signals, considering an APOE background, include high levels of and . Our findings nominate several new transcripts, taking a combined approach to network building including known LOAD risk loci.

References

Bhoj E, Haye D, Toutain A, Bonneau D, Nielsen I, Lund I . Phenotypic spectrum associated with SPECC1L pathogenic variants: new families and critical review of the nosology of Teebi, Opitz GBBB, and Baraitser-Winter syndromes. Eur J Med Genet. 2018; 62(12):103588. PMC: 6594898. DOI: 10.1016/j.ejmg.2018.11.022. View

Haas C, Hung A, Citron M, Teplow D, Selkoe D . beta-Amyloid, protein processing and Alzheimer's disease. Arzneimittelforschung. 1995; 45(3A):398-402. View

de Torrente L, Zimmerman S, Suzuki M, Christopeit M, Greally J, Mar J . The shape of gene expression distributions matter: how incorporating distribution shape improves the interpretation of cancer transcriptomic data. BMC Bioinformatics. 2020; 21(Suppl 21):562. PMC: 7768656. DOI: 10.1186/s12859-020-03892-w. View

Trani E, Giorgi A, Canu N, Amadoro G, Rinaldi A, Halban P . Isolation and characterization of VGF peptides in rat brain. Role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem. 2002; 81(3):565-74. DOI: 10.1046/j.1471-4159.2002.00842.x. View

Elmer B, Kimberley McAllister A . Major histocompatibility complex class I proteins in brain development and plasticity. Trends Neurosci. 2012; 35(11):660-70. PMC: 3493469. DOI: 10.1016/j.tins.2012.08.001. View

Zlokovic B . Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol. 2013; 70(4):440-4. PMC: 4414030. DOI: 10.1001/jamaneurol.2013.2152. View

Watson E, Fargali S, Okamoto H, Sadahiro M, Gordon R, Chakraborty T . Analysis of knockout mice suggests a role for VGF in the control of fat storage and energy expenditure. BMC Physiol. 2009; 9:19. PMC: 2774661. DOI: 10.1186/1472-6793-9-19. View

Saadi I, Alkuraya F, Gisselbrecht S, Goessling W, Cavallesco R, Turbe-Doan A . Deficiency of the cytoskeletal protein SPECC1L leads to oblique facial clefting. Am J Hum Genet. 2011; 89(1):44-55. PMC: 3135813. DOI: 10.1016/j.ajhg.2011.05.023. View

McGeer P, McGeer E, Yasojima K . Alzheimer disease and neuroinflammation. J Neural Transm Suppl. 2000; 59:53-7. DOI: 10.1007/978-3-7091-6781-6_8. View

10.

Mastroeni D, Chouliaras L, Grover A, Liang W, Hauns K, Rogers J . Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer's disease pathophysiology. PLoS One. 2013; 8(1):e53349. PMC: 3540085. DOI: 10.1371/journal.pone.0053349. View

11.

Piehowski P, Petyuk V, Orton D, Xie F, Moore R, Ramirez-Restrepo M . Sources of technical variability in quantitative LC-MS proteomics: human brain tissue sample analysis. J Proteome Res. 2013; 12(5):2128-37. PMC: 3695475. DOI: 10.1021/pr301146m. View

12.

Myers A, Gibbs J, Webster J, Rohrer K, Zhao A, Marlowe L . A survey of genetic human cortical gene expression. Nat Genet. 2007; 39(12):1494-9. DOI: 10.1038/ng.2007.16. View

13.

Bu Y, Lederer J . Integrating additional knowledge into the estimation of graphical models. Int J Biostat. 2021; 18(1):1-17. DOI: 10.1515/ijb-2020-0133. View

14.

Soliman N, Okuse K, Rice A . VGF: a biomarker and potential target for the treatment of neuropathic pain?. Pain Rep. 2019; 4(5):e786. PMC: 6882576. DOI: 10.1097/PR9.0000000000000786. View

15.

Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 45(12):1452-8. PMC: 3896259. DOI: 10.1038/ng.2802. View

16.

von Bernhardi R, Cornejo F, Parada G, Eugenin J . Role of TGFβ signaling in the pathogenesis of Alzheimer's disease. Front Cell Neurosci. 2015; 9:426. PMC: 4623426. DOI: 10.3389/fncel.2015.00426. View

17.

Rodin A, Gogoshin G, Hilliard S, Wang L, Egelston C, Rockne R . Dissecting Response to Cancer Immunotherapy by Applying Bayesian Network Analysis to Flow Cytometry Data. Int J Mol Sci. 2021; 22(5). PMC: 7956201. DOI: 10.3390/ijms22052316. View

18.

Bennett D, Wilson R, Boyle P, Buchman A, Schneider J . Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012; 72(4):599-609. PMC: 3490232. DOI: 10.1002/ana.23654. View

19.

Webster J, Gibbs J, Clarke J, Ray M, Zhang W, Holmans P . Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009; 84(4):445-58. PMC: 2667989. DOI: 10.1016/j.ajhg.2009.03.011. View

20.

Wisor J, Takahashi J . Regulation of the vgf gene in the golden hamster suprachiasmatic nucleus by light and by the circadian clock. J Comp Neurol. 1997; 378(2):229-38. View